Mechanism of action: Tramadol ER balliculeVisual mnemonic: Tramadol ER mascot “Ultra-ram Trauma doll”
What it isExtended-release mu-opioid agonist and serotonin-norepinephrine reuptake inhibitor (ULTRAM ER, 2005); around-the-clock chronic pain.
Why this oneOnce-daily delivery is unsuitable for as-needed pain or rapid titration; apparent half-life ~8 h (vs ~6 h IR).
What limits itCYP2D6 inhibition can blunt analgesia while seizures and serotonin toxicity remain. It retains full opioid dependence and respiratory risk.
BOXED WARNING Addiction/abuse/misuse; life-threatening respiratory depression (swallow whole); accidental ingestion; risks with benzodiazepines/CNS depressants; NOWS; Opioid REMS; ultra-rapid metabolism in children (contraindicated <12 y and <18 y post-tonsillectomy/adenoidectomy); CYP3A4/2D6 interactions
FDA dosing
Population
Start
Target
Max
Severe and persistent pain requiring an opioid, not adequately treated by alternatives (incl. IR opioids); not for PRN use
Adults
100 mg QD (tramadol IR: 24-hr IR dose rounded down to next lower 100 mg increment QD)
Titrate by 100 mg every 5 days to adequate analgesia
300 mg/day
Titration Increase by 100 mg every 5 days
Renal Severe (CLcr <30 mL/min): do not use (not studied; limited dose flexibility)
Hepatic Severe (Child-Pugh C): do not use (not studied; limited dose flexibility)
Some patients on tramadol IR may not be able to convert (limited dose flexibility); elderly: titrate slowly, extra caution >75 y
Instructions
Once daily at about the same time each day
Swallow whole with liquid; do not crush, chew, split, or dissolve
Take with or without food, but consistently
Do not use with other tramadol products
Do not abruptly discontinue — taper by ≤10% to 25% of total daily dose every 2 to 4 weeks
Discuss access to an opioid overdose reversal agent (e.g., naloxone, nalmefene)
Available strengths
ER tab 100, 200, 300 mg
Contraindications
Children younger than 12 years of age
Postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy
Significant respiratory depression
Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
Known or suspected gastrointestinal obstruction, including paralytic ileus
Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days
Cautions
Addiction, abuse, and misuse
Life-threatening respiratory depression
Risks with benzodiazepines/other CNS depressants
Neonatal opioid withdrawal syndrome
Opioid Analgesic REMS
Ultra-rapid metabolism / respiratory depression risk in children
CYP450 (3A4/2D6) interactions
Opioid-induced hyperalgesia and allodynia
Serotonin syndrome
Seizures
Suicide risk
Respiratory depression in chronic pulmonary disease, elderly, cachectic, debilitated
Adrenal insufficiency
Severe hypotension
Increased intracranial pressure, brain tumors, head injury, impaired consciousness
GI complications (sphincter of Oddi spasm)
Anaphylaxis and hypersensitivity
Withdrawal
Driving and operating machinery
Hyponatremia
Hypoglycemia
Adverse reactions
Dizziness
Nausea
Constipation
Headache
Somnolence
Flushing
Pruritus
Vomiting
Insomnia
Dry mouth
Pregnancy Prolonged use may cause NOWS; animal data suggest fetal risk; not recommended during or immediately before labor
Lactation Tramadol and M1 present in milk; breastfeeding not recommended (risk of infant sedation/respiratory depression)
Exposure dependenceTherapeutic exposure; severe toxicity requires meaningful MAO-A inhibition
Evidence confidenceHigh
InterpretationOpioid with clinically significant SRI activity; dangerous with meaningful MAO-A inhibition. A second SRI generally represents therapeutic duplication/additive adverse effects, not the classic life-threatening interaction.